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Abstract 
Introduction 
Bony metastases in cervical carcinoma are rare, occurring on average in 4.6% of patients. Autopsy studies 
indicate that it is underdiagnosed. It is important to recognise bony infiltration as palliative radiotherapy 
can relieve pain and prevent pathological fractures. As survival after the diagnosis of bone involvement 
is short, an appropriate palliative care plan should be tailored according to the patients’ limited 
prognosis. 
Methods 
A retrospective cohort analysis of women with cervical cancer, diagnosed between January 2014 and 
December 2015, was undertaken. Demographic, treatment and follow up data were collected for all 
women with bone metastases confirmed by imaging. Descriptive statistics were generated. 
Results 
The cohort study identified 642 patients with cervical carcinoma, of which 25 (3.89%) were diagnosed with 
bone involvement. Ten patients had bone involvement at diagnosis of cervical cancer and 15 had bone 
metastases at recurrence, occurring a median of 286 days after primary treatment. 
Survival after the diagnosis of bone metastases was short, with 88% of patients dying within the first 6 
months. Women with a low WHO performance status at diagnosis of bone metastases had a 
significantly shorter survival (p=0.024). When a previously described prognostic score was applied, those 
with a high score had a significantly shorter survival (median 61 days) than those with a low score 
(median 158 days) (p=0.0065). 
Conclusions 
Although bone metastases are rare in women with cervical cancer, they are important to recognise as 
radiotherapy is a useful modality for palliating bone pain and reducing pathological fractures. Health 
care workers should be vigilant, especially during the first 2 years of follow up, to increased analgesic 
use and chronic pain as these may indicate bone involvement. 
Use of a prognostic score is valuable in tailoring treatment and counselling patients and their families 
with regard to survival. Survival after the diagnosis of bone involvement is short and a patient’s quality 
of life may be greatly improved by an appropriate radiotherapy and palliative care plan. 
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Bone involvement in women with cervical cancer at Tygerberg Hospital 
Introduction 
Cervical cancer is the 2nd most common cancer in women after breast cancer in Sub Saharan Africa [1].  
Many women in South Africa present with late stage disease, due to poor access to the cervical 
screening programme and lack of knowledge regarding the disease [2].   
Metastases to bone or direct infiltration of cancer into bone, although rare, are important to recognize 
and diagnose as palliative radiotherapy treatment can then be timeously employed to relieve pain and 
improve quality of life.  This information also assists in determining prognosis and life expectancy, and 
could be used to tailor appropriate treatment plans. 
This descriptive study aims to describe the patient and tumour characteristics and treatment of cervical 
cancer patients with confirmed bone involvement at Tygerberg Hospital Gynaecologic Oncology Unit. 
Prevalence 
In a review article, including 5 studies with a total 4422 cervical cancer patients, the prevalence of bone 
metastases ranged from 1.8%  – 6.6 % with an average of 4.6% (205/4422) [3]. In a more recent study, 
Matsumiya et al. reported the prevalence of bone metastases in 5.8% (54/925) of women with cervical 
cancer treated between 1995 and 2014 at a cancer centre in Japan [4].  Two South African studies; the 
first of radiographic findings on 1347 women at cervical cancer diagnosis at Johannesburg General 
Hospital and the second, at Tygerberg Hospital, investigating the detection of bone metastases by bone 
scan at cervical cancer diagnosis in 540 patients; gave prevalences of bony involvement at diagnosis of 
4.6%  and 2.03% respectively [5,6]. A higher rate of bone involvement was reported at an autopsy study 
of bone metastasis in all gynaecological cancers [7]. Of the 112 cervical cancer patients who were 
autopsied, 20 (17.9%) were found to have bony involvement. Of these only 7 (6.3%) had pre-morbid 
radiographic evidence of bone metastasis, indicating that it is likely underdiagnosed. 
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Diagnosis 
Most patients with bone metastases are diagnosed at recurrence of disease, however a few women 
have bone involvement at cancer diagnosis [8].  Since cervical cancer is clinically staged, routine imaging, 
other than a chest x-ray and abdominal ultrasound, is seldom performed at diagnosis in a resource 
limited setting.  Follow up of treated cervical cancer patients includes a consultation and thorough 
physical examination.  Between 25-50% of recurrences are detected at routine follow up visits, the rest 
are at diagnosed in patients presenting with symptoms [9].  Physical examination has the highest 
detection rate for recurrence when compared to cytology and imaging modalities. There are insufficient 
data to support routine use of imaging to detect recurrence [10].  Further investigations at diagnosis and 
follow up are performed based on abnormalities found at examination or on symptoms reported by the 
patient. 
 
Symptoms 
Pain is the most common presenting symptom of patients with bony involvement [4,8].  Neurological 
deficit, pathological fracture and fatigue can be present in isolation or in combination with pain [8]. 
More than 50% of patients have extra skeletal metastases at time of diagnosis of bone metastasis, most 
frequently in the lung [8,11].  The most common sites for bone involvement are the lumbar spine 
followed by the pelvis, thoracic spine and ribs. Bone metastases have also been reported in the upper 
and lower extremities although this is rare [12,13]. 
There are 4 proposed mechanisms of metastasis to the skeleton: 1. Pelvic or parametrial tumour growth 
directly into the pelvic bones; 2. Direct extension from other soft tissue metastasis, such as lung into ribs 
or brain metastasis into skull; 3. Dissemination to the spine by way of Batson’s venous plexus; 4. Distant 
haematogenous metastasis to extremities [3].   
As mentioned before, imaging is not performed routinely at each follow up visit, however if patients 
have constant pain that is not responsive to analgesia, bony metastasis should be considered.   
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Imaging 
Plain x-rays are used as a first line investigation for detecting bony involvement because they are 
inexpensive and accessible, however sensitivity and specificity are low.  A second investigation is usually 
required to confirm metastases [14].  Bone scintigraphy is useful for detecting bone pathology, and has 
the added advantage of imaging the whole skeleton, however it is not very specific.  A historic study at 
Tygerberg hospital using bone scintigraphy to detect bony involvement at diagnosis of cervical cancer 
had a false positive rate of 8% (43/540 scans) and a pick-up rate of 2.03%. Degenerative and arthritic 
changes, congenital bone lesions, trauma and previous fractures were the most common explanations 
for the false positive results [6].  Brodowitz et al. published a recent review on the current 
recommendations for monitoring bone health in the cancer patient [14].  Table 1 shows the advantages 
and disadvantages of the various imaging modalities . 
A small study of 20 patients compared axial MRI to whole body bone scintigraphy for detection of bone 
metastases in patients with solid tumours.  They concluded that MRI was more sensitive and specific 
than bone scintigraphy for metastases in the spine, as well as providing information on tumour 
infiltration into structures surrounding the vertebrae, which impacts on therapeutic decisions.  As bone 
scintigraphy included the entire skeleton, it was useful in detecting metastases outside of the spine in 
the appendicular skeleton [15]. 
Whole body MRI and whole body (18F)-2-fluoro-2-deoxyd-glucose (FDG) PET/CT were compared for 
diagnostic accuracy in detecting bone metastases in 109 patients with either malignant melanoma or 
small cell lung carcinoma.  Metastases were detected in 10% (11/109) of patients and there was no 
significant difference in the diagnostic ability of the two imaging modalities [16]. 
 
In a retrospective study more specific to the detection of bone metastases in cervical cancer, Liu et al. 
compared CT scan and MRI to FDG-PET/CT [17].  They included 233 imaging pairs to compare CT and PET 
and 245 imaging pairs to compare PET with MRI. They found that PET was more sensitive than CT, and 
more specific than MRI.  The other advantage of PET/CT is that lymph node metastases are also 
detected. Using multivariate analysis of risk factors (including age; FIGO stage; histological type; tumour 
differentiation and extent of lymph node involvement) for haematogenous bone metastases at primary 
staging, lymph node extent was the only significant predictor of bone metastases [17]. 
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Table 1. Advantages and disadvantages of imaging modalities for the detection of bone metastases  
 
Imaging modality Advantages Disadvantages 
Plain radiography • Widely available and inexpensive • Widely available and inexpensive 
Radionuclide 
bone scintigraphy 
• Relatively inexpensive 
• Evaluates whole skeletal system 
• Provides information on osteoblastic activity and skeletal  vascularity 
• More sensitive than plain radiography 
• Low specificity for bone metastases 
• Cannot directly detect osteolytic metastases 
 
CT • Higher resolution than plain radiography and provides three-dimensional 
anatomical information 
• Modality of choice for evaluating cortical bone (e.g. the ribs) 
• Excellent soft tissue and contrast resolution; soft tissue extension of bone 
metastases is easily visualized 
• Useful to localize lesions for biopsy 
• Low specificity for bone metastases 
MRI • Higher resolution than plain radiography and additional three-
dimensional anatomical information 
• Highly sensitive (95%) for detection of bone metastases 
• Multi-planar images permit imaging of the entire spine in the sagittal 
plane 
• Excellent for demonstrating bone marrow infiltration 
• Preferred imaging method for spinal cord compression and subsequent 
planning of surgery or radiation therapy 
• Superior to C-choline PET/CT for detecting bone metastases 
• Not suitable for evaluating cortical bone 
• Cost-effectiveness of newer MRI modalities (e.g. whole- 
body or axial MRI) unclear 
 
SPECT • Superior sensitivity and specificity to bone scintigraphy 
• Axial slices provide better localization of radionuclide uptake than 
bone scintigraphy 
• Cannot generate absolute quantification values 
• Whole-body scanning not possible in a reasonable time frame 
• Less widely available and more costly than other imaging 
modalities 
18FDG–PET • Superior sensitivity to bone scintigraphy 
• Allows visualization of functional aspects 
• Role in routine practice unclear 
• Less widely available and more costly than other imaging 
modalities 
11C-choline 
PET/CT 
• Higher specificity than bone scintigraphy and MRI, with fewer 
indeterminate lesions 
 
• May not provide greater sensitivity than bone 
scintigraphy 
• Cost-effectiveness unclear 
• Less widely available and more costly than other imaging 
modalities 
Abbreviations: C, carbon; CT, computed tomography; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography; SPECT, single-photon 
emission computed tomography. 
 
Taken from Brodowicz, T., et al., Early identification and intervention matters: A comprehensive review of current evidence and recommendations 
for the monitoring of bone health in patients with cancer.
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
9 
 
In a recent retrospective study, patients were selected based on positive histology from bone biopsy 
specimens. A total of 409 biopsies and 748 images were used to calculate the diagnostic characteristics of 
each of the different imaging modalities. A summary of the findings is shown in Table 2. Once again 
PET/CT and MRI were the top performing modalities, with MRI being more accurate for spine metastases 
and PET/CT more accurate for non-spine lesions [18]. 
 
 
Table 2. Diagnostic characteristics of the imaging modalities (reported with 95% conﬁdence intervals). 
 
X-ray (n = 223) CT (n = 233) MRI (n = 209) BS (n = 35) PET/CT (n = 58) 
Sensitivity 33.0(23.6–43.6) 75.6(67.8–82.6) 90.5 (83.7–95.2) 74.1 (53.7–88.8) 92.3  (79.1–98.3) 
Speciﬁcity 96.1 (91.2–98.7) 89.2 (81.1–94.7) 81.1 (73.6–89.8) 62.5 (24.7–91.0) 63.2 (38.4–83.7) 
Accuracy 69.5 (63.0–75.5) 81.1 (75.5–85.9) 87.1 (81.8–91.5) 71.4 (53.7–85.4) 82.7 (70.6–91.4) 
PPV 86.1 (70.5–95.3) 91.4 (84.7–95.8) 86.8 (79.4–92.2) 87.0 (66.4–97.1) 83.7 (69.3–93.2) 
NPV 66.3 (59.1–73.0) 70.9 (61.8–79.0) 87.5 (78.7–93.6) 41.7 (15.3–72.3) 80.0 (51.9–95.4)  
 
Abbreviations: negative predictive value (NPV); positive predictive value (PPV). 
Taken from: Lange, M.B., et al., Diagnostic accuracy of imaging methods for the diagnosis of skeletal malignancies:  
A retrospective analysis against a pathology-proven reference. 
 
 
Risk factors 
The risk of developing distant metastases after chemoradiation for cervical cancer was investigated by 
Schmid et al.  The most important factors were lymph node involvement and FIGO stage of disease. 
Eleven percent of patients staged Ib to IIIa with negative nodes developed distant metastases with a 91% 
3 year distant metastases-free survival  (DMFS), while 38% of patients stage IIIb to IVa or with positive 
nodes developed distant metastases with a 67% 3 year DMFS. They also showed that in the group with 
positive nodes, the lower the number of chemotherapy cycles given during radiation the higher the risk 
for developing distant metastases.  The number of chemotherapy cycles had no impact on metastases in 
the low risk group [19].  
Poorly differentiated tumours and histological types other than squamous carcinoma, such as small cell 
neuroendocrine, clear cell and adenoid cystic carcinoma, were found to have a greater tendency to 
spread to bone in a retrospective study [3].  Advanced FIGO stage and a greater extent of lymph node 
metastases have both been linked to bone metastases. In univariate analysis of 165 cervical cancer 
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patients, FIGO stage and extent of lymph node metastases were both associated with the development of 
bone metastases, however only extent of lymph node metastases was significant on multivariate analysis. 
Patients with lymphatic spread to pelvic, para-aortic or inguinal nodes, supraclavicular, and mediastinal 
lymph nodes had a 2%, 6%, 11%, and 55% incidence of haematogenous bone metastases. There were no 
patients with bone metastases and negative nodes [17]. 
Risk factors associated with the earlier development of bone metastases in patients with cervical cancer 
were investigated by Yoon et al.  Over a 17 year period they treated 2013 patients with cervical cancer of 
whom 105 developed bone metastases (5.21%). After multivariate analysis the risk factors that remained 
significant for shorter time to the development of bone metastases were advanced (IIb – IVb) vs early 
FIGO stage (I and IIa); Adenocarcinoma (vs Squamous and Adenosquamous) and if patients developed 
multiple bone metastases (vs single metastases). There was no significant difference in survival after the 
diagnosis of bone metastases (average 10 months) with any of these risk factors. Those patients who 
received salvage radiotherapy to the bone metastases had a longer survival than those that only received 
chemotherapy (12 versus 7 months) [11]. 
 
 
Timeline 
The median time from diagnosis of cervical cancer to onset of bone metastases varies from 16 months 
(range 2-203 months) to 27 months (range 0-279 months), with a wide range [8,11]. In 75% of patients, 
bone metastases develop within 3 years after diagnosis of cervix cancer [3]. Yoon et al. showed a 
significantly shorter time to develop bone metastases with adenocarcinoma than squamous cell 
carcinoma (12 vs 29 months; p=0.0016) and with late stage disease versus early stage disease (15 vs 22 
months; p=0.02). Median survival after the diagnosis of bone metastases is short, ranging from 3.5 
months to 17 months [3,11].  In one study 81% of patients died within 1 year and 95% within 2 years after 
bone metastases were detected [3]. Matsumiya et al. investigated factors which influence survival after 
the detection of bone metastases from cervical cancer. After multivariate analysis, 5 factors proved to be 
significant: Synchronous extraskeletal metastasis; WHO performance status of 3 to 4; onset time at initial 
presentation (at diagnosis or recurrence); multiple bone metastases and a bone metastasis-free interval 
of less than 12 months. They used these 5 factors to develop a prognostic scoring system, where 1 point 
was allocated for each significant factor. The 26 week survival in patients with a score of 2 was 61.4% and 
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was only 12.5% for those with a score ≥ 4. The median survival for those patients with a score of ≥ 4 was 
13 weeks [4]. This information is very helpful in planning treatment, especially when it comes to spinal 
surgery for bone metastasis, where a 3-6 month life expectancy is a prerequisite. 
 
Treatment  
Radiotherapy has been shown to be an effective palliative treatment for bone pain due to metastatic 
cancer [20]. There are many different radiotherapy regimes including single dose and multiple fraction 
protocols, with marked variation in the fractionation prescribed according to geographical location and 
practice setting (university/academic vs private) [21]. A Cochrane review investigated the efficacy of 
single fraction radiotherapy in comparison to multiple fraction radiotherapy for relieving bone pain from 
metastatic cancer. Eleven trials with 3435 patients were included in the systematic review. Complete pain 
relief was reported in one third of patients with partial pain relief in 60% of patients.  There was no 
difference in efficacy in relieving bone pain between single fraction and multiple fraction regimes. There 
was also no difference between the risk of spinal cord compression with single or multiple fraction 
radiotherapy. Retreatment was higher in the single fraction group, although this was confounded by the 
fact that radiotherapists are less likely to retreat after giving multiple fractions. The risk of developing a 
pathological fracture was also slightly higher in the group that received single fraction radiotherapy (3% 
vs 1.7%) [22]. An update on this systematic review, including 25 trials, confirmed the results of the 
Cochrane review and suggested that single fraction radiotherapy should be implemented as standard of 
care for palliation of uncomplicated bone metastasis [23]. Taking into account the burden of a multiple 
fraction regime on the radiotherapy centre, the time and cost to the patient of attending for numerous 
treatments and the reduced life expectancy of these patients, it seems appropriate that a single fraction 
should be the standard protocol. Eight Gray as a single fraction is considered to be the most cost effective 
and convenient treatment with the least acute toxicity [24]. 
Recently a European panel issued a consensus guideline that advocates the use of bisphosphonates in 
early breast cancer, not only for bone health due to the use of tamoxifen, aromatase inhibitors and 
castration, but also for delaying onset of bone metastases [25]. In patients that already have skeletal 
metastases, bisphosphonates, such as Zoledronic acid, and target therapies, such as denosumab, are 
approved in Europe and United States for reducing skeletal related events (SRE’s), including spinal cord 
compression, pathological fractures and vertebral collapse [26]. Studies on Zolendronic acid have shown 
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that it delays the time to SRE and reduces pain from bone metastases [27].  Most studies on 
bisphosphonates have been carried out in patients with breast, prostate and lung cancer where bone 
metastases are a common event, occurring in 65 – 75% of patients with breast or prostate cancer. 
Although bone involvement is rare in cervical cancer, bisphosphonates may play a role in reducing SRE’s, 
palliating pain and improving quality of life. 
Life expectancy after the development of bone metastases from cervical cancer is short, with 95% of 
patients dying within 2 years. It is important to identify risk factors that may reduce life expectancy, so 
that the treatment offered is of an appropriately short duration and offers maximal palliation.  This study 
aims to study patients with bone metastases from cervical cancer at Tygerberg Hospital in order to 
identify common risk factors and tailor a more suitable follow up schedule for those who are at high risk.    
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Aims and Objectives 
- To estimate the prevalence of bone metastases occurring in patients with cervical cancer at Tygerberg 
Hospital. 
- To describe the patient and cervical tumour characteristics in women with bone metastases. 
- To identify common risk factors in patients with bone metastases in order to tailor their follow up 
schedule. 
- To educate doctors treating patients with cervical cancer to be aware of the symptoms of bone 
metastases and of the value of palliative radiotherapy for pain relief by publication of a manuscript. 
 
Methods 
This study is a cohort analysis of folders of patients with confirmed cervical cancer who attended the 
Tygerberg Gynaecology Oncology Unit for their initial visit between January 2014 and December 2015.  
Patients were identified from the gynaecological-oncology records, which were assessed for imaging 
studies which confirmed bone metastases. Their general folders, gynaecological-oncology and radiation 
oncology folders were accessed for further information and follow up data.  
Patients were initially clinically staged together with basic imaging including chest x-ray, abdominal 
ultrasound and a cystoscopy to rule out bladder metastases. A CT scan was used for planning 
radiotherapy fields. The standard protocol of 45-50 Gray to the pelvis with concomitant weekly Cis-
platinum followed by 25 Gray given as brachytherapy to the cervix was offered to patients who were 
treated with curative intent. This protocol was modified for patients not tolerating treatment and for 
those treated with palliative intent. From 2015 onwards many patients with FIGO stage IIIb cervical 
cancer had PET/CT for radiotherapy planning. 
Follow up consisted of a clinical examination and specific investigations based on the patients symptoms 
every 3 months for the first 2 years, 6 monthly for the next 3 years and then yearly. Data was censored on 
15 January 2018. 
Descriptive statistics, means, medians and ranges were reported. Means were compared using the T-test 
with significance set at 0.05. Kaplan Meier estimates were used for survival analysis and survival curves 
were compared using the Rank-log method. Statistics were analysed using Social Science Statistics 
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(http://www.socscistatistics.com), and the Real Statistics Resource Pack software, Release 5.4 (www.real-
statistics.com) in Microsoft Excel 2010 was used to generate the Kaplan Meier estimates.  
The study was approved by the University of Stellenbosch Health Research Ethics Committee (Reference 
number S17/10/258). The patients’ names and any identifying characteristics remained confidential 
throughout the study, with only the principal investigator having access to the data list.   
 
Results 
Prevalence 
642 newly diagnosed cervical cancer patients attended the Gynaecological Oncology Unit between 1 
January 2014 and 31 December 2015.  25 patients (3.89%) were found to have radiological evidence of 
bone involvement. The mean age of women with bone metastases was 46 years (SD 11.28) with a range 
from 25 to 63 years. Six women were found to have bone involvement at initial staging and 4 women at 
imaging during radiotherapy treatment planning. The remaining 15 patients had bone metastases at 
recurrence. Their clinical details are found in table 3 and 4. 
 
Symptoms and sites of disease 
Pain was the main complaint in 24 out of 25 patients with bone involvement.  In addition, 4 women had 
neurological symptoms, including lower limb weakness and urinary retention due to spinal cord 
compression.  One patient was found to have a clavicular metastasis on PET scan and had no symptoms 
of bone pain.  
The sites of bony involvement were most commonly the pelvic bones (n=9) and lumbar spine (n=9). The 
thoracic spine (n=7), sacrum (n=5) and ribs (n=4) were the next common sites. Metastases were also 
found in the cervical spine (n=2), skull (n=2), clavicle (n=2), scapula (n=1) and mandible (n=1). Thirteen 
patients had multiple bone metastases. The distribution of sites is shown in Figure 1. 
With regard to imaging modalities, 4 patients were diagnosed with bone involvement on plain x-ray and 1 
on bone scan. Nine women had bone metastases found on PET scan, 6 on CT and 5 on MRI. 
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Figure 1. The distribution of bone metastases 
 
 
 
All 3 patients with neuroendocrine cervical tumours had bony involvement and extraskeletal metastases 
at cervical cancer diagnosis. Glassy cell type squamous carcinoma was diagnosed on one biopsy and this 
patient also presented with bony involvement and extraskeletal metastases.  The histology of the tumour 
in the remaining 21 patients was a moderately to poorly differentiated squamous cell cervical carcinoma. 
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Table 3. Characteristics of patients with bone involvement at primary diagnosis 
SCC – Squamous cell carcinoma, NET – neuroendocrine tumour, LN – lymph nodes 
Patient Age Clinical 
stage at 
diagnosis 
Histological 
type 
Site of bone met Other mets Imaging 
modality 
Therapy 
received 
Survival after 
bone met 
diagnosis 
(days) 
Survival from 
cancer 
diagnosis 
(days) 
1 49 IVb SCC 
Ilium, pubic ramus 
sacrum 
acetabulum 
LN X-ray 
RT 
10 Gy 1# 
30 30 
2 51 IVb SCC Thoracic spine 
Lung 
Liver 
CT 
RT 
10 Gy 1# 
117 129 
3 41 IVb NET 
Pelvis 
Femur 
Lung 
Liver 
LN 
MRI 
RT 
10 Gy 1# 
39 71 
4 29 IVb SSC Sacrum LN PET 
RT 
23.4 Gy 13# 
86 105 
5 27 IV b NET 
Ischium, pubic ramus, 
Cervical spine, Ribs, 
Skull 
Lung 
Liver 
Brain 
MRI 
RT 
8 Gy 1# 
53 53 
6 61 IV b Glassy cell 
Thoracic spine, 
R Clavicle 
Lung, LN, 
Bladder 
X-ray Analgesia 39 40 
7 34 III b SCC L acetabulum Lung, Liver, LN PET 
RT 
10 Gy 1# 
167 413 
8 51 III b SCC L Clavicle Lung, Liver, LN PET Analgesia 50 102 
9 62 III b  Lumbar vertebrae Lung Bone scan 
RT 
20 Gy 5# 
80 94 
10 35 III b SSC Sacrum None CT 
RT 
40.05 Gy 15# 
158 222 
Mean/
Median 
44       66.5 98 
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Table 4. Characteristics of patients with bone involvement at recurrence 
Patient Age Clinical 
stage at 
diagnosis 
Histological 
type 
Site of bone met Other 
metastases 
Imaging 
modality 
Therapy 
received 
Days from 
end of 
primary Rx 
to relapse 
Survival after 
bone met 
diagnosis 
(days) 
Survival from 
cancer 
diagnosis 
(days) 
11 39 II b SSC 
Ilium, sacrum, 
thoracic spine, rib 
Liver, LN PET 
RT 
6Gy 1# 
300 331 767 
12 57 II b SCC 
Thoracic 
vertebrae 
Lung CT 
RT 
8 Gy 1# 
319 36 484 
13 25 III b SCC R acetabulum Lung, LN PET Analgesia 171 115 419 
14 63 III b SCC 
Sacrum, Lumbar 
spine 
Lung, Liver, 
LN 
CT Analgesia 406 86 645 
15 50 II b SCC 
Thoracic spine, 
Lumbar spine 
Lung, pelvis MRI 
RT 
8 Gy 1# 
436 6 540 
16 60 III b SCC 
Cervical spine, 
Thoracic spine, 
Lumbar spine 
Lung, LN MRI 
RT 
20 Gy 5# 
63 72 274 
17 45 II b SCC Ilium Lung, LN PET 
RT 
15 Gy 5# 
299 286 664 
18 56 III b SCC Lumbar spine None X-ray Analgesia 286 78 461 
19 35 II b NET 
Lumbar spine, 
skull 
LN PET 
RT 
8 Gy 1# 
88 32 287 
20 55 III b SCC 
Cervical spine, 
thoracic spine, 
ribs, scapula, 
mandible 
Lung, LN PET 
RT 
12 Gy 3# 
203 71 379 
21 54 III b SCC Acetabulum, rib Pelvis, LN PET 
RT 
15 Gy 5# 
369 76 535 
22 42 III b SCC Ilium Bladder, LN MRI Analgesia 145 85 316 
23 49 IV b SCC Lumbar spine 
Lung, Liver, 
LN, ovaries 
CT Analgesia 3 138 353 
24 41 III b SSC Lumbar spine None X-ray
RT 
20 Gy 5# 
113 168 435 
25 39 II b SSC Lumbar spine LN CT Chemo 427 245 769 
Median
/mean 
47.3 286 85 461 
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At the time of diagnosis of bony involvement only 3 patients had no other metastases. The other 22 
patients all had metastases in multiple organs on imaging including lung (n=15); lymph nodes (n=18), 
liver (n=7); brain (n=1); bladder (n=2) and local recurrence in the pelvis (n=3). 
 
Timeline 
In those patients who had bony involvement at cancer recurrence, the time from presentation at the 
oncology clinic to the time of diagnosis of bone metastases was a median of 366 days (136 – 520 days). 
The time from the end of primary treatment to the diagnosis of bone involvement was a median of 286 
days (3-436). 
In all patients the time from diagnosis of bone involvement to death was a median of 80 days (6-331 
days).  Patients with bone involvement at cervical cancer diagnosis survived for a median of 66.5 days 
(30-167 days) and patients with bone involvement at recurrence survived for a median of 85 days (6-331 
days) after bone involvement was diagnosed. Although survival was shorter in those with bone 
involvement at diagnosis the means were not significantly different (p=0.242). 
Sixteen patients (64%) died within 3 months of diagnosis of bone involvement and 22 women (88%) died 
within 6 months. All patients had demised by 11 months after the diagnosis of bone involvement. The 
survival curve is shown in Figure 2. 
 
Risk factors 
Twelve patients had a single bone metastasis and survived for a median of 126.5 days (36-286 days) 
after diagnosis of the bone involvement. Multiple bone metastases were identified in 13 patients with a 
median survival of 71 days (6-331 days). A comparison of means was not statistically significant, 
however trended towards better survival in the patients with single bone metastasis (p=0.094). 
Extraskeletal metastases were found in 22 patients with a median survival of 78 days (6-331 days). Three 
patients had no extraskeletal metastases with a median survival of 158 days (78-168 days). The means 
were not significantly different (p=0.52). 
 
Stellenbosch University  https://scholar.sun.ac.za
19 
 
Figure 2. Kaplan-Meier Survival after the diagnosis of bone metastases 
 
 
 
WHO performance status was documented in 17 patients. Eight women had a performance status of 1-2 
with a median survival of 148 days (39-286). Nine women had a performance status of 3 or 4 with a 
median survival of 72 days (6-168 days). The T-test for comparison of means was statistically 
significantly different (p=0.024). 
Nine patients with recurrence had a bone metastases-free interval of more than 6 months after the end 
of primary cervical cancer treatment with a median survival after diagnosis of bone recurrence of 78 
days (6-331 days). In 6 patients the bone metastases-free interval was less than 6 months with a median 
survival of 100 days (32-168 days) which was not significantly different (p=0.529). Table 5 shows the 
comparison of means for the different prognostic parameters. 
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Table 5. Prognostic risk factors for survival after the diagnosis of bone involvement. 
Risk factor Number of 
patients (n) 
Median survival in days (range)  Comparison of 
means 
Primary bone metastases 10 66.5 days (30-167) 
p=0.242 Metastases at recurrence 15 85 days (6-331) 
Multiple bone metastases 13 71 days (6-331) 
P=0.094 Single bone metastasis 12 126.5 days (36-286) 
Extraskeletal metastases 22 78 days (6-331) 
P=0.52 No extraskeletal metastases 3 158 days (78-168) 
Performance status 1-2 8 148 days (39-286) 
P= 0.024 Performance status 3-4 9 72 days (6-168) 
<6 months after treatment 6 100 days (32-168) 
P= 0.529 >6 months after treatment 9 78 days (6-331) 
Prognostic score 1-2 9 158 days (36-286) 
P=0.0065 Prognostic score 3-4 8 61 days (6-117) 
 
 
A scoring system with 1 point given for each of primary bone involvement at diagnosis; multiple bone 
metastases; extraskeletal metastases and performance status 3 or 4 was assigned for the 17 patients 
with all these parameters documented. Nine patients had a score of 1-2 with a median survival of 158 
days (36-286 days) and 8 patients had a score of 3-4 with a median survival of 61 days (6-117 days). 
Survival was significantly better for those with a low score (p=0.0065).  The survival curve demonstrating 
this significance in survival is shown in Fig. 3. The p-value for the log-rank test = 0.0072 again confirming 
that these survival curves are significantly different. 
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Figure 3. Kaplan Meier survival curves comparing prognostic scores 
 
A: Prognostic score 1-2 
B: Prognostic score 3-4 
Scores according to Matsumiya et al. [4] 
 
Treatment  
Seventeen patients received radiation therapy for bone involvement. Of these, 9 patients received a 
single fraction with a dose ranging from 6 Gray to 10 Gray, with most receiving a dose of 8 Gray.  Two 
patients received 3 fractions with 4-5 Gray per fraction (12-15 Gray in total). Four patients received 5 
fractions with a total dose of 15-20 Gray. Three of these patients had spinal metastases with 
neurological deficit and one had a recurrence in the external iliac nodes with infiltration of the iliac bone 
and a good performance status. One patient received chemotherapy for an in-field recurrence. Two 
patients, who had bone involvement involving the sacrum at cancer diagnosis, received higher doses of 
radiation in an attempt to treat both the primary disease and the bone involvement. One patient 
received high dose palliative radiotherapy of 40.05 Gray in 15 fractions. The other patient died before 
completion of radiotherapy after receiving 23 Gray to the pelvis and sacrum. Five patients received only 
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treatment of bone metastases. There was no difference in mean survival between those that received 
radiation therapy for bone involvement and those that did not (p=0.544). 
Of the 15 patients with bone involvement at recurrence, 6 patients had received radical 
chemoradiotherapy for their primary tumours.  This entailed 46 Gray (FIGO Stage II disease) and 50.4 
Gray (FIGO stage III) with weekly Cis-platinum (40mg/m2) for 4 to 5 cycles. A further 6 patients had 
received  46 – 50.4 Gray but with only 1 or no cycles of Cis-platinum, usually due to renal impairment or 
hydronephrosis. There was no significant difference in the time from end of primary treatment to the 
development of bone metastases in these 2 groups (p=0.356). Single bone metastases occurred more 
often in those patients who received more than 1 cycle of Cis-Platinum (5 out of 6 patients) and 2 of 
these patients had no extraskeletal metastases at recurrence. The patients who did not receive Cis-
Platinum developed more multiple skeletal metastases (4 out 6 patients) and all had more than one 
extraskeletal metastasis at recurrence. One patient with a Neuroendocrine tumour received 
chemotherapy as primary cervical cancer treatment. Two patients with extensive disease received only 
10 Gray as a single fraction for palliation of their primary tumour with chemotherapy for extra-pelvic 
disease. 
 
Discussion 
Prevalence 
In this study 3.89% of patients diagnosed with cervical cancer developed bone metastases or had direct 
bony infiltration. Taking into account the dates for inclusion into this study, the minimum follow up time 
was 745 days (2 years and 14 days) and the maximum follow up time 4 years and 15 days. The longest 
duration from presentation at the gynaecology oncology clinic to the diagnosis of bone metastases at 
recurrence was 520 days, with a median of 366 days (136-520 days). 
In a study by Ratanatharathorn et al. over a 10 year period, 75% of patients had developed bone 
metastases within 36 months of cervical cancer diagnosis and 87.9% of patients within 5 years (median 
17 months) [3]. In a Japanese study over a 10 year period, 85% of patients with bone metastases were 
diagnosed within 2 years after completing treatment [28]. The median time from diagnosis of cervical 
cancer to diagnosis of bone metastases in a study by Thanapprapasr et al. was 16 months and by Yoon 
et al. was 27 months [8,11]. As our study was limited to 4 years it may be that we have only identified 
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about 80% of patients who will develop bone metastases and this would explain why our prevalence is 
lower than the reported literature (4.6%). Although not quantified in this study, a high loss to follow up 
of women with cancer is observed at our unit. 
There were fewer patients with bone involvement at diagnosis (1.56%; 10/642 patients), than previously 
reported at Tygerberg hospital (2.03%) or at Johannesburg General Hospital (4.6%) [5,6]. These are both 
historical studies published prior to the implementation of routine 10 yearly Papanicolaou smears in 
South Africa and this could partly be the reason why women in these earlier studies presented with 
more advanced disease. 
 
Symptoms and sites of disease 
As in most studies, pain was the most common symptom of bone involvement in 24 out of 25 patients. 
Four patients also had associated neurological symptoms. Similarly, Thanapprapasr et al. reported 37 
out 41 patients with pain as the presenting complaint, and 5 out of 41 women with neurological deficit 
[8].  In a pooled analysis of over 5500 patients with bone metastases from various cancers, the authors 
showed that pain and strong opioid use were significantly increased prior to a skeletal-related event 
such as a pathological fracture or spinal cord compression [29]. It is of importance therefore to monitor 
analgesic use carefully during follow up visits as a drastic increase may indicate a bone metastases or 
skeletal-related event. 
Over 60% of bone metastases from cervical cancer occur in the spine with the most common site being 
the lumbar spine (36.4-51.9%). Multiple bone metastases are diagnosed in over 50% of patients [4,11]. 
The findings in this study are similar with 70% of metastases occurring in the spine, 35% in the lumbar 
spine and multiple skeletal metastases diagnosed in 52% of patients. 
 
Imaging 
There was no standard imaging technique used to diagnose bone involvement in this study. All 
modalities (X-ray, bone scintography, CT scan, MRI and PET/CT) were employed to diagnose skeletal 
metastases. In 2015 PET/CT radiotherapy planning became routine in our unit for most patients with 
FIGO stage III cancer, however this did not lead to an increase in diagnosis of bone involvement, once 
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again supporting the evidence that routine imaging for detection of bone metastases at diagnosis is not 
warranted or cost effective [6]. PET/CT may be useful, however, to identify patients with lymph node 
involvement, as these patients are at high risk of bone metastases. Liu et al. showed that extent of 
lymph node involvement is a significant predictor of future haematogenous bone metastases [17]. 
Routine imaging is also not recommended in surveillance of patients after treatment of cervical cancer, 
however in patients with a clinical suspicion of recurrence, PET/CT may be an appropriate tool as it has a 
high specificity and sensitivity in detecting metastases and recurrent cancer.  
At the time of diagnosis of bone involvement only 3 (12%) patients had no extraskeletal metastases. Co-
existing metastases most commonly occurred in the lungs and lymph nodes. Extraskeletal metastases 
were similarly common in 92.6% (50/54) of patients as reported by Matsumiya et al., 78% (32/41) 
reported by Ratanatharathorn et al. and 53.6% (22/41) patients in a study done by Thanapprapasr et al. 
[3,4,8]. The most common sites for extraskeletal metastases in all studies were lungs, lymph nodes and 
liver. If a skeletal metastasis is identified at diagnosis or at recurrence it is important to consider further 
imaging, as more than 50% of patients will have co-existing extraskeletal metastases. 
 
Timeline 
Although risk factors such as non-squamous histology, advanced FIGO stage and extent of lymph node 
involvement have all been linked to the development of bone involvement, the time from cancer 
diagnosis to bone involvement varies widely. Most recurrences occur within 2 years of cancer diagnosis, 
however less than 50% are detected at routine follow up visits [9]. Skeletal metastases at recurrence 
were diagnosed a median of 366 days (136 – 520 days) after diagnosis of cervical cancer and a median of 
286 days (3-436) after the end of treatment. This is a shorter time than in other studies: Thanapprapasr 
et al. found a median of 16 months; while Yoon et al. reported a median time to bone involvement of 27 
months [8,11]. The follow up time in this study was limited to 4 years and therefore patients with late 
recurrences were not included, which may increase the median time. In the study by Yoon et al., 
patients initially staged with Stage I and IIa disease had a median duration of 22 months after cervical 
cancer diagnosis to development of bone metastases, while patients with advanced stage cervical 
cancer had a median time of 15 months [11]. There were no patients with FIGO stage I to IIa in this study 
cohort and therefore the median duration to development of bone involvement of 12 months (366 
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days) is more comparable to the median of 15 months in patients with advanced disease reported by 
Yoon et al. [11]. 
Survival after the diagnosis of bone metastases is short. In this study 88% (22/25) of patients had died by 
6 months after the bone involvement had been identified and all patients had demised by 11 months. 
The patients with bone involvement at diagnosis of cervical cancer had a shorter (though not 
significantly) survival than those with bone metastases at recurrence. This is not unexpected as these 
patients all had advanced stage disease at cervical cancer diagnosis. Survival time after bone metastases 
is consistently short as reported in other studies. Ratanatharathorn et al. reported a median survival of 
3.5 months, Matsumiya et al. a median survival of 5 months, Thanapprapasr et al. reported a median 
survival of 7 months and Yoon et al. a median survival of 10 months [3,4,8,11].  
Matsumiya et al. identified a number of independent factors which were associated with a poorer 
survival namely extraskeletal metastasis; performance status 3 to 4; multiple bone metastases; bone 
metastasis-free interval of <12 months and onset time at initial presentation, and used these 
parameters in a prognostic scoring system [4]. When these factors were analysed in our cohort, 
performance status was the only significant factor. The bone metastasis-free interval < 12 months was 
not applicable to patients with bone involvement at diagnosis (n=10) and therefore, in order to apply a 
prognostic score to our whole cohort, this parameter was omitted. A score of 3-4 was predictive of poor 
prognosis, with a median survival of 61 days, and this was statistically significant when compared to 
survival of patients with a score of 1-2. Although our cohort was too small to run multivariate analysis 
for the different factors, this scoring system has previously been validated in a larger study. Its use is 
valuable in planning treatment, especially in patients presenting with bone involvement at diagnosis 
where, if a lengthy treatment is planned, patients with a poor prognostic score may demise before 
completing radiation. It is also important for counselling the patient and family with regard to survival 
and in arranging a palliative care plan. 
 
Treatment 
Radiotherapy has been shown to be effective in treating bone metastases and palliating bone pain. As in 
many other studies, a wide range of different radiotherapy protocols were employed. For 
uncomplicated bone metastases a single fraction of 8 Gray has been shown to be effective and cost 
efficient [23]. Nine of the patients in this study received a single fraction. Of the other 8 patients that 
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received more than 1 fraction of radiation treatment, 3 had complicated spinal metastases with 
neurological fall-out and 2 received treatment for both the primary tumour and the bone involvement 
simultaneously. The reasons for the multiple fractions in the other 3 patients are unclear.  
Although Yoon et al. showed an improvement in survival in patients who were treated with 
radiotherapy compared to those treated with chemotherapy, this has not been corroborated by other 
studies [11]. In this study, survival in patients treated with radiotherapy for bone involvement was 
compared to no treatment and survival was not improved. The numbers in this study were not sufficient 
to make any conclusions regarding optimal treatment and there was no standardized treatment regime 
to allow comparison.  
The addition of adjuvant chemotherapy, over and above concomitant chemoradiotherapy, in high risk 
patients has been shown to decrease the risk of distant metastases and prolong survival [30]. The results 
of a large randomised control trial (Outback Trial) are awaited to corroborate these findings [31]. 
Adjuvant chemotherapy may be advocated in patients with locally advanced cancer to lower the risk of 
treatment failure, including bone metastases, at distant sites. 
Bisphosphonates have been shown to reduce the incidence of bone metastases and decrease major 
skeletal-related events such as pathological fractures, especially in women with low levels of sex 
hormones [25]. These studies have mostly included women with breast cancer who are either post-
menopausal or using aromatase inhibitors as an adjuvant. In post-menopausal women, bisphosphonates 
have shown an improvement in breast cancer survival. As women with advanced stage cervical cancer 
have been castrated by radiation therapy, it may be beneficial to include bisphosphonates in their 
therapy to improve bone health and decrease the risk of bone metastases. In those that already have 
bone involvement, bisphosphonates may decrease bone pain and the incidence of skeletal-related 
events.  
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Conclusions 
Although bone metastases are rare, patients with advanced disease, lymph node involvement and non-
squamous histology are at higher risk. Most recurrences, including bone metastases, occur in the first 2 
years of treatment. Health care providers should be vigilant during follow up to identify symptoms such 
as persistent pain or increased analgesic use in order to diagnose bone metastases as early as possible. 
Standard x-rays are easily accessible for diagnosis, but not very sensitive. If there is a high index of 
suspicion, an FDG/PET scan may be warranted as this will not only detect bone involvement, but also 
extra-osseous recurrence. If an x-ray confirms bone involvement, then further imaging should be done 
as more than 50% of patients will have other organ involvement.  
After the diagnosis of bone involvement has been made, performance status should be documented as 
this was the most predictive parameter of survival in our study. A prognostic score should be calculated 
to guide further radiotherapy treatment and for counselling of the patient and family. The use of 
bisphosphonates needs to be considered, however further studies with regard to use in patients with 
cervical cancer need to be undertaken. Although radiotherapy has not been shown to improve survival, 
it is very effective in palliating pain from bone infiltration. 
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CT  Computed Tomography 
DMFS  Distant metastases-free survival 
FDG-PET/CT (18F)-2-fluoro-2-deoxyd-glucose Positron Emission Tomography – Computed 
Tomography  
FIGO  International Federation of Gynecology and Obstetrics 
Gy  Gray 
LN  Lymph node 
MRI  Magnetic resonance imaging 
NET  Neuroendocrine tumour  
SSC  Squamous cell carcinoma 
SRE  Skeletal Related Event 
WHO  World Health Organisation 
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